Evidence map›Paper›PMID 40635245›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Plasmonic Mesoporous Gold-Based SERS Biosensor for Ovarian Cancer-Derived Extracellular Vesicles.

Javeria Bashir, Mostafa Kamal Masud, Asep Sugih Nugraha, Chia-Hung Liu, Arya Vasanth, Aditya Ashok, S M Azad Hossain, Emtiaz Ahmed, Tanja Pejovic, Terry Morgan and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. A Scalable Spin-Coating Strategy for Mesoporous Gold Thin Films toward miRNA Detection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Javeria BashirSchool of Mechanical and Mining Engineering, Faculty of Engineering, Architecture, and Information Technology (EAIT), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Mostafa Kamal MasudAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.ORCID 0000-0002-5346-3135
Asep Sugih NugrahaAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Chia-Hung LiuTMU Research Center of Urology and Kidney and Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, 250 Wu-Hsing Street, Taipei, 11031, Taiwan.
Arya VasanthAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Aditya AshokSchool of Mechanical and Mining Engineering, Faculty of Engineering, Architecture, and Information Technology (EAIT), The University of Queensland, Brisbane, Queensland, 4072, Australia.
S M Azad HossainAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Emtiaz AhmedAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Tanja PejovicDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, 97239-3098, USA.
Terry MorganDepartment of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, 97239-3098, USA.
John HooperMater Research Institute, The University of Queensland, South Brisbane, Queensland, 4101, Australia.
Andrew LaiTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, UQ Centre for Clinical Research (UQCCR), Faculty of Medicine, and UQ Centre for Extracellular Vesicle Nanomedicine, The University of Queensland, Brisbane, Queensland, 4029, Australia.
Dominic GuanzonTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, UQ Centre for Clinical Research (UQCCR), Faculty of Medicine, and UQ Centre for Extracellular Vesicle Nanomedicine, The University of Queensland, Brisbane, Queensland, 4029, Australia.
Yusuf Valentino KanetiSchool of Mechanical and Mining Engineering, Faculty of Engineering, Architecture, and Information Technology (EAIT), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Md Shahriar A HossainSchool of Mechanical and Mining Engineering, Faculty of Engineering, Architecture, and Information Technology (EAIT), The University of Queensland, Brisbane, Queensland, 4072, Australia.
Carlos SalomonTranslational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, UQ Centre for Clinical Research (UQCCR), Faculty of Medicine, and UQ Centre for Extracellular Vesicle Nanomedicine, The University of Queensland, Brisbane, Queensland, 4029, Australia.
Yusuke YamauchiAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, 4072, Australia.ORCID 0000-0001-7854-927X

Funding

Advance Queensland Fellowship Program AQIRF043-2020-CVARC Australian Laureate Fellowship FL230100095Donald & Joan Wilson Foundation Ltd. 2020000323Exploratory Research for Advanced Technology JPMJER2003JST-ERATO Materials Space-Tectonics Project JPMJER2003Medical Research Future Fund MRF1199984National Health and Medical Research Council NHMRC 1195451Next Generation Cancer Research Fellowship 2027070Ovarian Cancer Research Foundation OCRF 2018001167
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are lipids bilayer-delimited particles carrying bioactive molecules such as proteins, lipids, and nucleic acids, reflecting the physiological state of their origin. Found in biofluids like saliva, urine, blood, and peritoneal fluid, EVs serve as promising minimally invasive biomarkers for several conditions including cancer. However, achieving high sensitivity and specificity in EV detection remains technically challenging. Placental Alkaline Phosphatase (PLAP), an enzyme primarily expressed in the placenta during pregnancy, has emerged as a clinically relevant biomarker in gynecological malignancies, including ovarian cancer (OC). In this study, a nanoengineered mesoporous gold (mAu)-based Surface-Enhanced Raman Spectroscopy (SERS) platform is reported for the rapid and ultrasensitive detection of PLAP-positive EVs in OC patients. The mAu offers high surface roughness, enabling numerous localized plasmonic hotspots that amplify Raman signals and improve probe and antibody loading. This allowed the detection of as few as 100 EVs mL

Indexed as

Biosensing TechniquesExtracellular VesiclesGoldOvarian NeoplasmsSpectrum Analysis, RamanFemaleHumansPorosityGoldextracellular vesiclesliquid biopsymesoporous goldovarian cancersurface‐Enhanced Raman Spectroscopy (SERS)

Identifiers

PMID40635245
PMCPMC12393012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.